drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Autologous gene-modified T cells expressing a chimeric antigen receptor targeting CD19 on B cells to mediate targeted cytotoxicity.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor targeting CD19 on B cells. CAR engagement activates CD3zeta and costimulatory domains (e.g., CD28 or 4-1BB), driving T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity to eliminate CD19-positive malignant and normal B cells.
drug_name
Anti-CD19 CAR T cells
nct_id_drug_ref
NCT05744037